An FDA tool to hasten approvals isn't useful for breast cancer drugs - STAT

An FDA tool to hasten approvals isn't useful for breast cancer drugs - STAT

STAT Plus: An FDA tool for hastening approvals is not very useful for breast cancer drugs

By ED SILVERMAN

JUSTIN SULLIVAN/GETTY IMAGES

“If regulators approve drugs based on surrogate endpoints, they should be confident of what these surrogates tell us,” said study co-author Bishal Gyawali

READ MORE